Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Biotech
German cancer antibody biotech eyes SPAC as route to Nasdaq
Market turmoil may have frozen the traditional IPO pipeline, but Veraxa is turning to the SPAC model to hop onto the Nasdaq.
James Waldron
Apr 23, 2025 6:09am
ADCs to cell therapy: How AZ aims to 'redefine' oncology
Apr 9, 2025 11:44am
BioAtla lays off 30% of staff, hunts for ADC partners
Mar 28, 2025 6:30am
Immunocore bispecific reduces HIV reservoir in early trial
Mar 10, 2025 3:00pm
Amgen, CytomX ax T-cell engager after assessing data, priorities
Mar 7, 2025 5:39am
AbbVie pays Xilio $52M upfront in latest T-cell engager deal
Feb 12, 2025 8:29am
